Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics plc

Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report), Bicycle Therapeutics (BCYC – Research Report) and Envist...

Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Bicycle Therapeutics (BCYC)

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Bicycle Therapeutics, with a price target of $44.00. The company’...

Oppenheimer Remains a Buy on Bicycle Therapeutics (BCYC)

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Bicycle Therapeutics, with a price target of $15.00. The company’...

Barclays Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)

TD Cowen analyst Tara Bancroft maintained a Buy rating on Bicycle Therapeutics today. The company’s shares opened today at $8.18. According to TipR...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BCYC	$6.32	+2.43%	284.41K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BCYC	$6.32	+2.4%	284.41K
3
4
5
6

BCYC

BCYC

Dividend Overview

Get Bicycle Therapeutics plc Data in Excel

Get Bicycle Therapeutics plc Data in Excel